Cargando…
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer deaths in both men and women in the United States, carrying a 5-year survival rate of approximately 5%, which is the poorest prognosis of any solid tumor type. Given the dismal prognosis associated with PDAC, a more thorou...
Autores principales: | Reznik, Robert, Hendifar, Andrew E., Tuli, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3939680/ https://www.ncbi.nlm.nih.gov/pubmed/24624093 http://dx.doi.org/10.3389/fphys.2014.00087 |
Ejemplares similares
-
Pancreatic cancer cachexia: a review of mechanisms and therapeutics
por: Tan, Carlyn R., et al.
Publicado: (2014) -
Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016) -
Meta-analyses of treatment standards for pancreatic cancer
por: GONG, JUN, et al.
Publicado: (2016) -
Influence of Body Mass Index and Albumin on Perioperative Morbidity and Clinical Outcomes in Resected Pancreatic Adenocarcinoma
por: Hendifar, Andrew, et al.
Publicado: (2016) -
Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics
por: Murthy, Divya, et al.
Publicado: (2018)